IRCT20200105046010N95招募中Unknown
In-vivo Bioequivalence Study of Empagliflozin/Metformin 5/500 mg FC. Tablets of The Test Drug (JARINOMET® 5/500 mg Tab. Kharazmi Pharma, Iran) in Compared with The Reference Drug (SYNJARDI® 5/500 mg. Boehringer Ingelheim Germany) In Iranian Healthy Volunteers
Kharazmi Pharmacy0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Empagliflozin orMetoformin
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Empagliflozin-Metformin tablets with brand drug (Synjardy® 25/1000 mg, Boehringer Ingelheim, Germany)Bio equivalence test.IRCT20200105046010N60Pars Darou Pharmaceutical Company24
招募中
不适用
In-vivo Bioequivalence Test of Empagliflozin tablets with brand drug (JARDIANCE® 25 mg, Boehringer Ingelheim , Germany)Bio equivalence test.IRCT20200105046010N49Pars Darou Pharm. Co.24
已完成
Unknown
Bioequivalence study of Empagliflozin 5 mg/ Metformin 1000 mg film coated tablet manufactured by Modava Pharmaceutical CompanyIRCT20130313012810N22Modava Pharmaceutical Company24
尚未招募
不适用
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditionsIRCT20180620040164N13ACtover Pharmaceutical Co26
招募中
不适用
Bioequivalence study of Empagliflozin 25 mg tablet in 24 healthy male under fasting conditionsBioequivalence investigation of the generic Actoverco. Empagliflozin 25 mg tablet with brand Jardiance 25 mg tablet Boehringer..IRCT20180620040164N19Actover Pharmaceutical Co.24